InflaRx

Update in progress

IFRX (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

InflaRx N.V. is a clinical-stage biopharma focused on inhibitors of the C5a inflammatory pathway, targeting autoimmune and inflammatory diseases. Its lead candidate, vilobelimab, is a first-in-class anti-C5a antibody in Phase 3 for early septic organ dysfunction. Izicopan targets C5aR and is in Phase 2a; IFX002 is a preclinical vilobelimab-based asset. Partnerships include Staidson, Catalent, and U.S. government collaborations. Founded 2007, based in Jena, Germany.

Company score

Sentiment: 0.16; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.01; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.05; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.01; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.07; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive